Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors
Authors:
- Camila B. XavierCXCamila B. Xavier
- Carlos Diego H. LopesCLCarlos Diego H. Lopes
- Beatriz M. AwniBABeatriz M. Awni
- Eduardo F. CamposECEduardo F. Campos
- João Pedro B. AlvesJAJoão Pedro B. Alves
- Anamaria A. CamargoACAnamaria A. Camargo
- Gabriela D. A. GuardiaGGGabriela D. A. Guardia
- Pedro A. F. GalantePedro A. F. Galante
- Denis L. JardimDJDenis L. Jardim
Open Access
Abstract
Purpose: Solid tumors harboring tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb) received agnostic approval for pembrolizumab. This work aims to analyze the somatic mutational profile’s influence on the outcomes of patients with TMB-high tumors treated with immune checkpoint inhibitors (ICIs). Methods: This post-hoc analysis evaluated clinical and molecular features of patients with solid tumors treated with ICIs that could be either monoclonal antibody directed against programmed cell death protein-1 or monoclonal antibody directed against programmed cell death ligand 1 (anti-PD-1/anti-PD-L1), monoclonal antibody directed against cytotoxic T lymphocyte-associated antigen (anti-CTLA-4) or a combined treatment regimen including one anti-PD-1/anti-PD-L1 and one anti-CTLA-4 (ICIs combination). We performed OS analysis for TMB thresholds of ≥10, ≥20, and p < 0.005). Among TMB ≥10 mut/Mb patients, mutations in E2F3 or STK11 correlated with worse OS, and mutations in NTRK3, PTPRD, RNF43, TENT5C, TET1, or ZFHX3 with better OS. These associations were confirmed with univariate and multivariate analyses (p < 0.05). Melanoma histology and TMB above the median endowed patients with better OS (p < 0.05), while MSI status, age, and gender did not have a statistically significant effect on OS. Conclusion: Combining TMB and mutation profiles in key cancer genes can better qualify patients for ICI treatment and predict their OS.Keywords
This publication has 26 references indexed in Scilit:
- Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancersJournal for ImmunoTherapy of Cancer, 2019
- Microsatellite-Stable Tumors with High Mutational Burden Benefit from ImmunotherapyCancer Immunology Research, 2019
- lifelines: survival analysis in PythonJournal of Open Source Software, 2019
- Biological Consequences of MHC-II Expression by Tumor Cells in CancerClinical Cancer Research, 2019
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 2019
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicAnnals of Oncology, 2018
- Tumor Mutational Burden and Response Rate to PD-1 InhibitionNew England Journal of Medicine, 2017
- Microsatellite instability: an updateArchives of Toxicology, 2015
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012